Updates on immunotherapy in non-small cell lung cancer

Expert Opinion on Biological Therapy

Volumn 14, Issue 4, 2014, Pages 411-418

  Shimanovsky, Alexei ^a   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Anti cytotoxic T lymphocyte antigen 4; Anti programmed death 1; Anti programmed death 1 ligand; Cytotoxic T lymphocyte antigen 4; Immunotherapy; Lung cancer; Programmed death 1 ligand

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MK 3475; MPDL 3280; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MELANOMA; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84896131876     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.887675     Document Type: Review

References (30)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
2. Rosell R, Moran T, Carcereny E, et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 2010;12:75-80
3. Shablak A, Sikand K, Shanks JH, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 2011;34:107-12
4. Grimaldi AM, Cassidy PB, Leachmann S, et al. Novel approaches in melanoma prevention and therapy. Cancer Treat Res 2014;159:443-55
5. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
6. Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012;12:923-37.
7. Drake CG, Lipson EJ, Brahmer Jr. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37
8. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:1452-8
9. ClinicalTrial.gov. A randomized trial to study the safety and efficacy of EGF cancer vaccination in late-stage (IIIB/IV) non-small cell lung cancer patients (NSCLC). Available from: ClinicalTrial. gov [Last accessed 20 November 2013]
10. Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011;33:369-83
11. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
12. ClinicalTrials.gov. Liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Available from: http://clinicaltrials.gov/[Last accessed 20 November 2013]
13. ClinicalTrials.gov. Phase IIB/III Of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available from: clinicaltrials.gov [Last accessed 20 November 2013]
14. The Oncology Report. Vaccine extended overall survival in subset of NSCLC patients. Available from: http://www. oncologypractice.com/index.php? id=5740&cHash=071010&tx-ttnews% 5Btt-news%5D=218169 [Last accessed 20 November 2013]
15. Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013;13:1413-27
16. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
17. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
18. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
19. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83.
20. ClinicalTrials.gov. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: http://clinicaltrials.gov [Last accessed 20 November 2013]
21. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
22. Probst HC, McCoy K, Okazaki T, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6:280-6
23. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
24. Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab(Anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in phase I trial. In Journal of Thoracic Oncology. 2013. vol 8, Supplement 2.] (Abst: M018.03). Available from: http://www. 2013worldlungcancer.org/documents/WCLC2013-AbstractBook. pdf
25. Rizvi N, Antonina JS, Chow LQ, et al. A phase I study of nivolumab (anti-PD- 1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31(Suppl):abstract 8072
26. ClinicalTrial.gov. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Available from: http://clinicaltrial.gov [Last accessed 20 November 2013]
27. Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC) International Association for the Study of Lung Cancer. (Abst: M018.02). Available from: http://abstracts. webges.com/myitinerary/session- 116.html?congress=wclc2013
28. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
29. Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). The European Cancer Congress 2013. (Abst: 3408). Available from: http://eccamsterdam2013.ecco-org.eu/Scientific- Programme/Abstract-search.aspx? abstractid=6899
30. Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic Non-small cell lung cancer (NSCLC). J Clin Oncol 2013;31(Suppl):abstract 8008